Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
Deep diving into bitcoin ETFs trading day
CNBC’s Kate Rooney and Bob Pisani join ‘Power Lunch’ to discuss bitcoin ETFs trading day.
A point-of-sale system like Square on steroids
A New York City cowboy boot store may sell classic styles, but it’s been improving its sales by using technology and analytics on the Bindo POS iPad app.
Goldman downgrades key defense stocks to sell
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Morgan Brennan joins ‘Power Lunch’ to report on Goldman Sachs’ sweeping downgrade of key stocks in the defense sector. 03:57 Fri, Jan 13 20232:43 PM EST
Hopes for ‘accelerated’ stimulus are driving stocks higher: Strategist
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Investors seem to be expecting a “massive” stimulus from the Democratic sweep of Congress, according to Jim Lowell, CIO of Adviser Investments. 00:00 Fri, Jan 8 20212:43 AM EST
The momentum in the Nasdaq can continue, it’s not overbought, says Ritholtz’s Josh Brown
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Josh Brown, Ritholtz Wealth Management CEO, joins ‘Closing Bell’ to discuss the Nasdaq’s momentum, big bank earnings expectations, and his market outlook. 04:19 Wed, Jan 10 20243:17 PM EST
Lightning Round: IBM is inexpensive and ‘a pretty good stock’, says Jim Cramer
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email ‘Mad Money’ host Jim Cramer weighs in on viewer stock picks including: MBIA, Whirlpool, Carnival Cruise Line, Modine Manufacturing, DraftKings and IBM. 04:49 Thu, Dec 14 20237:52 PM EST
